Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pulmonx (LUNG) Long-Term Debt Repayments (2022 - 2025)

Pulmonx (LUNG) reported Long-Term Debt Repayments of $1000.0 for Q3 2025, down 97.92% on a QoQ basis from $48000.0 in Q2 2025.

Pulmonx (LUNG) has 4 years of Long-Term Debt Repayments data on file, last reported at $1000.0 in Q3 2025.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $1000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $98000.0 (up 8.89% YoY) and the FY2024 annual result came in at $95000.0, up 1.06% from the prior year.
  • Long-Term Debt Repayments fell to $1000.0 in Q3 2025 per LUNG's latest filing, from $48000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $49000.0 in Q4 2024 and bottomed at $1000.0 in Q3 2025.
  • The 4-year median for Long-Term Debt Repayments is $47000.0 (2023), against an average of $37600.0.
  • The widest annual swing landed in 2023, when Long-Term Debt Repayments climbed 9.3%; it then increased 4.26% in 2024.
  • Tracing LUNG's Long-Term Debt Repayments over 4 years: stood at $43000.0 in 2022, then grew by 9.3% to $47000.0 in 2023, then climbed by 4.26% to $49000.0 in 2024, then tumbled by 97.96% to $1000.0 in 2025.
  • Per Business Quant, the three latest LUNG Long-Term Debt Repayments figures stand at $1000.0 (Q3 2025), $48000.0 (Q2 2025), and $49000.0 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Pulmonx 67.30 Mn -2.45 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 1,000.00
Sep 30, 2025 1,000.00
Jun 30, 2025 48,000.00
Jun 30, 2025 48,000.00
Dec 31, 2024 49,000.00
Dec 31, 2024 49,000.00
Dec 31, 2023 47,000.00
Dec 31, 2023 47,000.00
Dec 31, 2022 43,000.00
Dec 31, 2022 43,000.00